Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of eight systematic review(s)/meta-analysis(es). ^[1-8]
• In chronic phase-chronic myeloid leukemia (CP-CML) patients with prior exposure to ≥2 tyrosine kinase inhibitors (TKIs), ponatinib achieved major molecular response (MMR) rates between 19.0-66.7%, compared to asciminib (23.3-25.5%), omacetaxine (19.2%), and bosutinib (13.2%) over 6 months.
• Complete cytogenetic response (CCyR) rates for ponatinib ranged from 21.4-64.8%, with asciminib at 38.7-40.8%, bosutinib at 18-24.2%, and omacetaxine at 16.1% after 6 months. Ponatinib 45 mg was superior in CCyR, major cytogenetic response (MCyR), and complete hematologic response (CHR) relative to lower doses and other TKIs.
• In philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), next-generation TKIs, including ponatinib, achieved a complete molecular remission (CMR) rate of 82% versus 53% with imatinib, and improved survival in nontransplant patients to levels comparable to allogeneic hematopoietic stem cell transplant (allo-HSCT) in measurable residual disease (MRD)-negative patients.
• Ponatinib presents a high risk of arterial occlusion events in patients with CML and has a significantly increased incidence of severe adverse events compared to other treatment regimens.
• Among second- and third-generation TKIs, ponatinib exhibits the highest risk of hypertension (17% incidence) and is associated with elevated risks of hepatotoxicity, particularly high-grade elevations in alanine transaminase (ALT) and aspartate transaminase (AST) levels, as well as increased occurrences of cardiovascular events, thrombocytopenia, pancreatic, and hepatic adverse effects relative to imatinib.
• There is no population types or subgroups information available in the reviewed studies.